Prognostic value of residual disease biology and gene expression changes during the neoadjuvant treatment in HER2-positive early-breast cancer.
- Citation:
- Meeting Instance:
- SABCS 2023
- Year:
- 2023
- Type:
- Abstract
- Sub type:
- Poster General
- Funding:
- NCTN
- Endpoint:
- Secondary-not-in-original
- Analysis:
- Primary
- Data Sharing:
- No-Data-Sharing
- Status:
- Presented/Published
- Citation Status:
- Note:
- Methodological:
- No
- Biospecimen:
- No
- SDC:
- No
- Parents:
- None
- Children:
- None
- Pharmas:
- GSK
- Grants:
- U10CA180821, U10CA180882; U10CA180868
- Corr. Author:
- Authors:
- Aranzazu Fernandez-Martinez Maki Tanioka Sung Gwe Ahn Paola Zagami Tomás Pascual Mattia Rediti Gong Tang Katherine A. Hoadley David Venet Naim U. Rashid Patricia A. Spears N. Islam Sandra M. Swain Christos Sotiriou Aleix Prat Charles M. Perou Lisa A. Carey
- Networks:
- CAPITAL, LAPS-NC007
- Study
- CALGB-40601
- Multiple Studies, or Legacy Studies in Alliance Study:
- Phases:
- 3
- Keywords: